Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

Qian, Yong; Guo, Junming; Chen, Yansong; Cui, Zhaolei; Chen, Yan

doi:10.2147/cmar.s320541

Cited by 5 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a clinical study of patients with hepatocellular carcinoma, plasma HSP90a has been found to be of diagnostic value for early hepatocellular carcinoma, and the combination of AFP can improve the diagnostic efficiency (22). We can also see the diagnostic value found in other tumor studies, such as colorectal cancer (21), nasopharyngeal carcinoma (49), lung cancer (64). In this study, plasma HSP90a in the malignant tumor group was significantly higher than that in the normal group (P < 0.001).…”

Section: Discussionmentioning

confidence: 81%

“…In a study of the diagnostic and prognostic value of HSP90α in gastric cancer, HSP90α of plasma was not associated with survival in patients with gastric cancer ( 48 ). While HSP90α was identified as an independent prognostic factor for nasopharyngeal carcinoma by univariate and multivariate Cox proportional risk regression analysis in a clinical study ( 49 ). A retrospective study measured HSP90α levels before and after treatment in 231 patients with lung cancer and found that HSP90α levels were associated with lung cancer treatment response and patient outcomes ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors

2022

View full text Add to dashboard Cite

Heat shock protein 90α (HSP90α) encoded by the HSP90AA1 gene, is the stress inducible isoform of the molecular chaperone HSP90, and was demonstrated as a promising hallmark to diagnose, prognosis in malignant tumors. This study is to evaluate the value of HSP90α in diagnosis, prognosis and immunotherapy of malignant tumors by investigating the expression of HSP90α in plasma of various tumors and analyzing the expression of HSP90α at gene and protein levels via pan-cancer database. We founded that levels of HSP90α in malignant tumors groups were significantly higher than healthy controls in serum. Pan-cancer analysis showed that HSP90AA1 was highly expressed in 27 of 33 tumors, but low in individual cancers (such as renal malignancies). The plasma HSP90α level was positively correlated with the stage of malignant tumor, but there was no significant difference between HSP90AA1 and the stage of most tumors. Cox regression analysis showed that HSP90AA1 expression was significantly correlated with OS in only 6 of the 32 cancers, including LIHC, KIRC, HNSC, LUAD, BRCA and MESO. Up-regulation of HSP90AA1 in most tumors was positively correlated with PDCD1LG2 and CD274 immune checkpoint genes. T cell CD8+ was positively correlated with HSP90AA1 in COAD, DLBC and UVM, and negatively correlated with HSP90AA1 in ESCA, GBM, HNSC, KIRC, KIRP, UCEC and STAD. The AUC of HSP90α are generally high in different tumor groups, which indicated its diagnostic value in malignant tumors. In conclusion, serum HSP90α in patients with malignant tumor is generally elevated, which is of positive significance as an independent diagnosis and combined diagnosis. However, we found that the expression level of HSP90AA1 gene in most tumors was not completely consistent with the serum level, and even down-regulated in some tumors. Plasma levels can be used as biomarkers of poor prognosis in some tumors, but it cannot be used as a biomarker for poor prognosis of all tumors, and more in-depth studies are needed.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors

2022

View full text Add to dashboard Cite

show abstract

“…However, these tests are not without limitations in terms of reliability [50][51][52]. The use of viral load quantification alongside serologic tests seems to enhance sensitivity and specificity [53][54][55], although not all studies support this observation [56,57].…”

Section: Discussionmentioning

confidence: 99%

A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens

Melouli,

Khenchouche,

Taibi-Zidouni

et al. 2023

Viruses

View full text Add to dashboard Cite

Nasopharyngeal cancer (NPC) is a prevalent type of cancer that often takes the form of undifferentiated carcinoma in the Maghreb region. It affects people of all ages. NPC diagnosis, mainly based on detecting Epstein-Barr virus (EBV), has not been well evaluated in North Africa. We compared the classical EBV serological tests using indirect immunofluorescence to the detection of EBV DNase antibodies by immunoblot in Algerian NPC patients. Significant variations were observed among different age groups of patients regarding the presence of VCA-IgA antibodies (0–14 and ≥30 years old, p < 0.0001; 15–19 and ≥30 years old, p < 0.01) and EA-IgA (0–14 and ≥30 years old, p < 0.01; 15–29 and ≥30 years old, p < 0.05). Differences were also noted in the titers of IgA anti-VCA and anti-EA antibodies across the three age groups. Some patients under the age of 30 with detectable IgG anti-VCA antibodies had undetectable IgA anti-VCA antibodies. These patients had a strong anti-DNase IgA response. However, older individuals had a higher level of anti-DNase IgG. Before treatment, children had strong DNase reactivity as indicated by specific IgA antibodies. Young adults had high IgA anti-DNase response, but the elderly (90.9%) had a lower response for these antibodies. Following therapy, the children retained high levels of IgA anti-DNase antibodies, and 66% of the young adults demonstrated robust antibody reactivity against DNase. In contrast, IgG responses to anti-DNase were low in children. This study demonstrated the utility of anti-DNase responses in the diagnosis and prognosis of NPC.

show abstract

Histogram analysis of quantitative parameters from synthetic MRI: correlations with prognostic factors in nasopharyngeal carcinoma

Yang

et al. 2023

Eur Radiol

View full text Add to dashboard Cite

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma

Cited by 5 publications

References 52 publications

Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors

Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors

A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens

Histogram analysis of quantitative parameters from synthetic MRI: correlations with prognostic factors in nasopharyngeal carcinoma

Contact Info

Product

Resources

About